Flot.bio x Philip Hemme

• Thomas Lingelbach, Valneva | Vaccines, Lyme Disease | E47

  Valneva now has three commercialized vaccines, and a Lyme disease candidate in Phase 3. Philip quizzes CEO Thomas Lingelbach about everything. They also discuss the current political turbulence with vaccines, especially in the US, and how it is impacting the industry.⭐️ ABOUT THE SPEAKERA veteran in the development of more than ten vaccines, Thomas has spent over 30 years in the vaccine space and has served in senior roles at the companies Intercell, Novartis and Chiron. Thomas was with Intercell since 2006 and was the CEO when the company merged with Vivalis to form Valneva in 2013.🔗 LINKS MENTIONEDValneva’s website - https://valneva.com/Valneva’s Half Year 2025 Financial Results - https://valneva.com/press-release/valneva-reports-half-year-2025-financial-results-and-provides-corporate-updates/Lovisa Afzelius, Flagship Pioneering 🇸🇪 | Company building, AI | E24https://flot.bio/episode/lovisa-afzelius-flagship-pioneering/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/thomas-lingelbach-valneva-vaccines/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ Timestamps[00:00:00] Intro[00:03:09] Duck cell vaccines[00:04:55] The grandpa of French and Austrian biotech[00:15:09] Products for chikungunya, Japanese encephalitis and cholera[00:22:04] Valneva and Pfizer’s Lyme disease vaccine[00:29:46] Navigating US anti-vaccine turbulence[00:33:33] The stormy biotech investment market[00:36:32] Thomas Lingelbach talks financials[00:39:46] Quick-fire questions

  --------  

  44:27

  --------

  44:27
• Marc de Garidel, Abivax 🇫🇷 | Ulcerative Colitis, Inflammation | E46

  When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes.Philip meets Abivax CEO Marc de Garidel in Vienna, Austria, to go behind the scenes of a remarkable biotech turnaround.Marc discusses the processes involved in executing the phase 3 trial that beat even Abivax’s own phase 2 data. He also talks about France’s biotech ecosystem and the importance of having the right team.⭐️ ABOUT THE SPEAKERMarc de Garidel joined Abivax as CEO in 2023. Prior to this, he led two biotech companies through billion-dollar exits (CinCor Pharma and Corvidia Therapeutics). He also served as CEO of Ipsen from 2010 to 2016, and has worked at the likes of Amgen and Eli Lilly.🔗 LINKS MENTIONEDAbivax’s website - https://www.abivax.com/Phase 3 results - https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week$747.5 million public offering - https://ir.abivax.com/news-releases/news-release-details/abivax-announces-closing-7475-million-public-offeringMarc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) | E09 - https://flot.bio/episode/marc-de-garidel-abivax-exit/Chris Martin, Verona Pharma 🇬🇧 | Ohtuvayre, COPD, Execution | E34 - https://flot.bio/episode/chris-martin-verona-pharma-copd/Christophe Bourdon, LEO Pharma 🇩🇰 | Biopharma Turnaround | E31https://flot.bio/episode/christophe-bourdon-leo-pharma-biopharma/Nanobiotix episode - https://www.youtube.com/watch?v=3Krhyy6a-nw&pp=0gcJCQMKAYcqIYzvFabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43 - https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/📜 TRANSCRIPT Read the full transcript here:💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS0:44: Abivax’s crazy Ph3 data and stock price jump4:06: Surging investor demand on NASDAQ and Euronext8:58: Future directions11:02: Executing a Phase 3 home run17:20: Marc de Garidel's leadership style21:58: Abivax: origins34:51: France's billion-dollar biotechs44:11: Quick-fire questions

  --------  

  53:40

  --------

  53:40
• Laurent Levy, Nanobiotix 🇫🇷 | Nanoparticles, Radiotherapy | E45

  As Philip travels to France, Nanobiotix CEO Laurent Lévy discusses how the company broke into Europe’s exclusive $1 billion biotech club, alongside the likes of Abivax and Medincell. They also chat about what it means to partner with giants like Johnson & Johnson, and how Laurent’s leadership style has evolved over his long tenure.⭐️ ABOUT THE SPEAKERLaurent Lévy co-founded Nanobiotics in 2003 and has served as CEO ever since. Before this, he worked in a variety of roles with companies including Altran Technologies, Valbiotis and Sanofi.He has a doctorate in nanomaterials-focused physical chemistry from the Pierre and Marie Curie University in Paris.🔗 LINKS MENTIONEDNanobiotix website -- https://nanobiotix.com/Nanobiotix's $71 million deal with Healthcare Royalty -- https://ir.nanobiotix.com/news-releases/news-release-details/nanobiotix-announces-strategic-royalty-monetization-agreementNanobiotix's first phase 1 data -- https://ir.nanobiotix.com/news-releases/news-release-details/nanobiotix-announces-first-data-phase-1-study-evaluating-jnj📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/laurent-levy-nanobiotix-nanoparticles-radiotherapy/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:02:11] Soaring stocks with clinical results[00:04:08] Nanobiotix's history[00:07:39] Nanoparticles and radiotherapy[00:13:42] Developing NBTXR3[00:25:02] Universal cancer radiotherapy enhancers[00:28:28] Few competitors[00:33:37] Biotech in France, Europe and the US[00:37:19] Laurent Lévy’s leadership style[00:42:16] Quick-fire questions

  --------  

  50:03

  --------

  50:03
• Gerrit Sitters, LUMICKS 🇳🇱 | CAR-T therapy, Single-Cell Analysis | E44 [Sponsored]

  As Philip tours Amsterdam, he visits the biotech tools startup LUMICKS. Founded in 2014, the firm offers products analyzing the binding interactions between molecules and cells, with applications in drug development, CAR-T therapies, and manufacturing.Philip sits down with co-founder Gerrit Sitters to discuss the company’s trajectory, the cyclic biotech investment market, and lessons from spinning the firm out from Vrije Universiteit Amsterdam.---Explore how LUMICKS' technology helps develop biologics and cell therapies with unique cell avidity data — http://bit.ly/lumicks---⭐️ ABOUT THE SPEAKERGerrit co-founded LUMICKS in 2014 following a PhD at Vrije Universiteit Amsterdam, and co-invented the technology behind LUMICKS’ main products. Gerrit now serves as Head of Product, where he aims to deploy the company’s products to tackle challenges in the life sciences.🔗 LINKS MENTIONEDLUMICKS’ website - https://www.lumicks.com/NanoTemper: https://flot.bio/episode/philipp-baaske-nanotemper-boostrapping-biotech/DNA Script: https://flot.bio/episode/thomas-ybert-dna-script-dna-printing/Adaptimmune: https://flot.bio/episode/adrian-rawcliffe-adaptimmune/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/gerrit-sitters-lumicks-car-t-therapy/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:02:09] The history of LUMICKS[00:08:33] Visualizing microscopic interactions[00:14:29] Improving drug development[00:20:33] AI and digital labs[00:29:53] Quality control and manufacturing applications[00:31:58] Single-cell analysis and CAR-T[00:46:13] LUMICKS’ future milestones[00:47:13] Cyclic biotech market[01:00:15] Gerrit Sitters’ career takeaways[01:18:01] Quick-fire questions

  --------  

  1:24:33

  --------

  1:24:33
• Fabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43

  We travel to the offices of Pharming Group in Leiden, the Netherlands, to chat with the newcomer CEO Fabrice Chouraqui.Fabrice discusses the fascinating history of Pharming, with its first commercial drug RUCONEST produced in the milk of transgenic rabbits. He also talks about the growth of Pharming from a protein therapy-focused biotech into a European multi-asset heavyweight, with a market cap of at least €800 million. ⭐️ ABOUT THE SPEAKERFabrice Chouraqui has been the CEO of Pharming Group since March 2024. Prior to this, he was a CEO-Partner at the US biotech venture capital firm Flagship Pioneering as well as CEO of the Flagship portfolio company Cellarity.He also served at Novartis and Bristol-Myers-Squibb for 10 years each, with his career beginning in R&D at pharmaceutical companies that were predecessors to today’s Sanofi. 🔗 LINKS MENTIONED- Pharming Group’s website - https://www.pharming.com/- Pharming Group’s second quarter and first half 2025 financial results - [https://www.pharming.com/sites/default/files/imce/Presentations/Pharming 2Q25_1H 2025 presentation_31JUL2025_website.pdf](https://www.pharming.com/sites/default/files/imce/Presentations/Pharming%202Q25_1H%202025%20presentation_31JUL2025_website.pdf)- Stefano Portolano, Azafaros 🇳🇱 🇨🇭 | Rare Diseases, Small Molecules | E40 -https://flot.bio/episode/stefano-portolano-azafaros-rare-disease/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:02:12] Kicking off at Pharming- [00:04:26] RUCONEST and transgenic rabbits- [00:06:57] Path to profitability- [00:13:43] Encouraging stock price trends- [00:17:39] The protein and small molecules portfolio- [00:28:13] Switching gear to commercialization - [00:33:40] European biotech success stories- [00:39:55] Lessons from Fabrice Chouraqui’s career- [00:47:29] Quick-fire questions

  --------  

  54:48

  --------

  54:48

More Science podcasts

Trending Science podcasts

About Flot.bio x Philip Hemme